Keywords: fda, panel, turns, down, schering-plough, temodal, melanoma
FDA panel turns down Schering-Plough's Temodal for melanoma
Article | 29 March 1999
Schering-Plough's new anticancer drug Temodal (temozolomide) should notbe approved for the treatment of advanced melanoma patients, according to the US ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
